Theriva Net Invested Capital from 2010 to 2025

TOVX Stock  USD 1.47  0.15  9.26%   
Theriva Biologics Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital will likely drop to about 28.6 M in 2025. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
42.8 M
Current Value
28.6 M
Quarterly Volatility
19.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.19. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Theriva Biologics over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Theriva Biologics' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Theriva Net Invested Capital Regression Statistics

Arithmetic Mean19,851,667
Geometric Mean15,396,437
Coefficient Of Variation100.14
Mean Deviation15,847,542
Median11,308,000
Standard Deviation19,879,706
Sample Variance395.2T
Range72.7M
R-Value0.55
Mean Square Error295.1T
R-Squared0.30
Significance0.03
Slope2,298,441
Total Sum of Squares5928T

Theriva Net Invested Capital History

202528.6 M
202442.8 M
202337.2 M
202252.1 M
202165.4 M
2020-7.2 M
2019-2.9 M

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Net Invested Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital42.8 M28.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.